PDGFRB and renal cell carcinoma: Pazopanib, an oral small molecule TKI targeting vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, stem cell factor receptor (SCF, c-kit), and platelet-derived growth factor receptors (PDGFR) α and β, is approved for the treatment of mRCC patients based on phase III trial that showed a significant prolongation in progression-free survival (PFS) compared to placebo in patients with advanced RCC [3].